Cognitive Behavioral Therapy for Cancer-related Fatigue in Patients With Cancer Receiving Palliative Systemic Treatment
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 15, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a type of therapy called cognitive behavioral therapy (CBT) to help reduce severe fatigue in cancer patients who are receiving palliative treatment. Palliative treatment focuses on improving quality of life for patients with serious illnesses, and fatigue is a common and challenging symptom for these patients. The study aims to see if a web-based version of CBT, guided mainly by nurses, can help reduce fatigue as effectively as traditional face-to-face therapy with psychologists. This online approach hopes to be more accessible for patients, making it easier for them to receive support without needing to meet in person as often.
To participate, individuals must be at least 18 years old, speak Dutch, and be receiving specific types of cancer treatment, like chemotherapy or immunotherapy, while experiencing significant fatigue. They'll start with an initial face-to-face session with a psychologist and their nurse to set goals, then continue with 12 weeks of online therapy modules. Regular check-ins with their nurse will help track progress and make adjustments. The study is currently recruiting participants, and those interested should discuss their eligibility with their healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Receive systemic treatment with palliative intent for a solid tumor.
- • Treatments include chemotherapy, targeted therapy, immunotherapy, and hormone therapy, possibly combined with surgery and/or radiation therapy
- • Are ≥18 years old
- • Are proficient in Dutch
- • Report severe fatigue (Checklist Individual Strength, fatigue severity subscale \[CIS-fatigue\] score ≥35) with no known somatic explanation other than cancer and/or cancer treatment
- • A life expectancy of ≥6 months according to their oncologist
- • Access to a device with internet.
- Exclusion Criteria:
- • Symptomatic brain metastases
- • Have a poor performance status (Karnofsky \<70)
- • Are currently receiving treatment for a mental disorder.
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported